Huntington Ingalls Industries Inc vs Medtronic PLC — how do they compare? Huntington Ingalls Industries Inc trades at $328.1 (market cap $12.92B), while Medtronic PLC trades at $90.86 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 9× Huntington Ingalls Industries Inc's market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| HII | MDT | |
|---|---|---|
Market Cap | $12.92B | $116.07B |
Sector | Technology | Health |
52-Week High | $453.73 | $105.35 |
52-Week Low | $265.40 | $73.75 |
Enterprise Value | $15.84B | $134.82B |
Dividend Yield | 1.68% | 3.18% |
Signals from Pluang's Aura AI — not financial advice
HII trades at $328.43, down 0.72% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Recent news includes a $2.2 billion contract award for surveillance and intelligence capabilities, enhancing its defense portfolio. Valuation ratios show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
Outlook is positive due to contract wins and operational improvements, but risks include political headwinds and execution challenges. Analyst consensus price target is $359.67, suggesting 9.5% upside. Investment opportunity lies in margin expansion from submarine contracts, while monitoring defense budget volatility is key.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Trailing returns across standard periods
Latest headlines on both assets
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →